Kenneth Cusi, MD
University of Florida · University of Texas
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kenneth Cusi, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:36 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04501406 · Low-Dose Pioglitazone in Patients With NASH (AIM 2)University of Florida · recruiting · Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Steatohepatitis · principal investigator
- Ph2NCT03459079 · Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver DiseaseUniversity of Florida · completed · Nonalcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes (T2DM) · principal investigator
- Ph4NCT00227110 · Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)The University of Texas Health Science Center at San Antonio · completed · Nonalcoholic Steatohepatitis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:36 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Role of Screening and Early Intervention in Primary Care with Low-Dose Pioglitazone for Patients with T2DM and NASHR01DK120331 · NIDDK · UNIVERSITY OF FLORIDA · PI Kenneth Cusi · fiscal years 2020 to 2023Named on NCT04501406
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:36 UTC. The ranking covers the 200 most relevant of 10 PubMed records, and a shared surname and initials can bring in a namesake. All 10 on PubMed
- Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection.Proc Natl Acad Sci U S A · 2017195 citationsRCR 7.2
- Atypical B cells are part of an alternative lineage of B cells that participates in responses to vaccination and infection in humans.Cell Rep · 2021179 citationsRCR 8.3
- 99 citationsRCR 6.1
- 76 citationsRCR 4.5
- Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial.Lancet Infect Dis · 202269 citationsRCR 5.1
- Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial.Nat Commun · 202148 citationsRCR 3.0
- Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.Lancet Infect Dis · 202434 citationsRCR 5.5
- A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria.Sci Transl Med · 202232 citationsRCR 2.3
- 6 citationsRCR 1.9